EP4333979A4 - Verfahren zur titration der dosis von psychedelika - Google Patents

Verfahren zur titration der dosis von psychedelika

Info

Publication number
EP4333979A4
EP4333979A4 EP22799340.9A EP22799340A EP4333979A4 EP 4333979 A4 EP4333979 A4 EP 4333979A4 EP 22799340 A EP22799340 A EP 22799340A EP 4333979 A4 EP4333979 A4 EP 4333979A4
Authority
EP
European Patent Office
Prior art keywords
psychedelics
titration
dose
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22799340.9A
Other languages
English (en)
French (fr)
Other versions
EP4333979A1 (de
Inventor
Robert Barrow
Daniel R. Karlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Definium Therapeutics US Inc
Original Assignee
Mind Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mind Medicine Inc filed Critical Mind Medicine Inc
Publication of EP4333979A1 publication Critical patent/EP4333979A1/de
Publication of EP4333979A4 publication Critical patent/EP4333979A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of Radiation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dental Preparations (AREA)
EP22799340.9A 2021-05-03 2022-05-01 Verfahren zur titration der dosis von psychedelika Pending EP4333979A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183579P 2021-05-03 2021-05-03
PCT/US2022/027179 WO2022235529A1 (en) 2021-05-03 2022-05-01 Method of titrating dose of psychedelics

Publications (2)

Publication Number Publication Date
EP4333979A1 EP4333979A1 (de) 2024-03-13
EP4333979A4 true EP4333979A4 (de) 2025-01-15

Family

ID=83932279

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22799340.9A Pending EP4333979A4 (de) 2021-05-03 2022-05-01 Verfahren zur titration der dosis von psychedelika

Country Status (7)

Country Link
EP (1) EP4333979A4 (de)
JP (2) JP2024517194A (de)
AU (2) AU2022268891A1 (de)
CA (1) CA3216939A1 (de)
IL (1) IL308068A (de)
TW (1) TW202245767A (de)
WO (1) WO2022235529A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102207640B (zh) * 2010-03-30 2014-05-28 比亚迪股份有限公司 具有液晶气泡的tft液晶显示器的回收方法
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
EP4329759A4 (de) 2021-04-30 2025-07-16 Mind Medicine Inc Lsd-salzkristallformen
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
US20230064429A1 (en) 2021-08-19 2023-03-02 Mind Medicine, Inc. IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
EP4387612A4 (de) 2021-08-20 2025-07-23 Pharmala Biotech Inc Zusammensetzungen mit nichtracemischen mischungen von (r)- und (s)-3,4-methylendioxymethamphetamin oder (r) und (s) n-methyl-1,3-benzodioxolylbutanamin und verwendungen davon
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170157343A1 (en) * 2014-06-30 2017-06-08 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
WO2020157569A1 (en) * 2019-01-30 2020-08-06 Diamond Therapeutics Inc. Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
WO2020169850A1 (en) * 2019-02-22 2020-08-27 Gh Research Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170157343A1 (en) * 2014-06-30 2017-06-08 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
WO2020157569A1 (en) * 2019-01-30 2020-08-06 Diamond Therapeutics Inc. Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
WO2020169850A1 (en) * 2019-02-22 2020-08-27 Gh Research Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "How to Microdose: A Step by Step Guide - Microdosing information, research, community, coaching and more.", 30 April 2021 (2021-04-30), pages 1 - 9, XP093230199, Retrieved from the Internet <URL:https://web.archive.org/web/20210430131601/https://microdosinginstitute.com/how-to/how-to-microdose/> *
KUYPERS KIM P.C.: "The therapeutic potential of microdosing psychedelics in depression", vol. 10, 27 August 2020 (2020-08-27), XP093229382, ISSN: 2045-1253, Retrieved from the Internet <URL:https://journals.sagepub.com/doi/pdf/10.1177/2045125320950567> DOI: 10.1177/2045125320950567 *
See also references of WO2022235529A1 *

Also Published As

Publication number Publication date
AU2022268891A1 (en) 2023-11-09
JP2024517194A (ja) 2024-04-19
TW202245767A (zh) 2022-12-01
WO2022235529A1 (en) 2022-11-10
EP4333979A1 (de) 2024-03-13
IL308068A (en) 2023-12-01
CA3216939A1 (en) 2022-11-10
AU2025217270A1 (en) 2025-08-28
JP2026076279A (ja) 2026-05-11

Similar Documents

Publication Publication Date Title
EP4069212A4 (de) Inhibitoren von hif-2alpha
EP4706684A3 (de) Zusammensetzungen und verfahren zur erhöhung der wirksamkeit von immuntherapien und impfstoffen
EP3634402C0 (de) Verfahren zur behandlung von zystischer fibrose
EP4289996C0 (de) Verfahren zur indizierung von nukleinsäuren
EP4065114C0 (de) Verfahren zur herstellung von relutrigine/prax-562
EP4744729A2 (de) Verfahren zur behandlung von gastrointestinalen stromatumoren
EP3277276A4 (de) Verfahren zur verabreichung von glutaminaseinhibitoren
EP3540433A4 (de) System zur schätzung der konzentration von bodeninjektionsmittel
EP3893883A4 (de) Verfahren zur behandlung von depression
EP3941921A4 (de) Therapeutische verfahren zur behandlung von hepatitis b
EP3897582C0 (de) Verfahren zur sprühtrocknung von semaglutide
EP3583521A4 (de) Verfahren zur ausführung von fraktionalen aktienaufträgen
EP4227290C0 (de) Verfahren zur wiederverwendung von dmtm
EP3578161A4 (de) Verfahren zur verbesserung der lagerstabilität von kosmetika
EP3833752A4 (de) Verfahren zur behandlung von mukopolysaccharidose typ ii
EP3826664A4 (de) Verfahren zur behandlung von mukopolysaccharidose typ i
EP3687538C0 (de) Verfahren zur behandlung von erhöhtem plasmacholesterin
EP3426632A4 (de) Inhibitoren der creb-cbp-interaktion zur behandlung von leukämie
EP3756133A4 (de) Verfahren zur authentifizierung von gegenständen
EP3786904C0 (de) Verfahren zur telematischen bereitstellung von fahrzeugkomponentenbewertung
EP4395815A4 (de) Verfahren zur verbesserung der stabilität von immuncheckpoint-inhibitoren
EP3816298A4 (de) Verfahren zur bestimmung der zytotoxizität von gas
EP3833780C0 (de) Verfahren zur detektion von vererbten myopathien in pferden
EP3761207C0 (de) Verfahren zur beauftragung von inhalten von blockkettenoperationen
EP3746102C0 (de) Verfahren zur isolierung von cytisin

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

TPAA Information related to observations by third parties modified

Free format text: ORIGINAL CODE: EPIDOSCTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0025000000

Ipc: A61K0031137000

A4 Supplementary search report drawn up and despatched

Effective date: 20241216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20241210BHEP

Ipc: A61K 31/675 20060101ALI20241210BHEP

Ipc: A61K 31/48 20060101ALI20241210BHEP

Ipc: A61K 31/4045 20060101ALI20241210BHEP

Ipc: A61K 31/137 20060101AFI20241210BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250919

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEFINIUM THERAPEUTICS US, INC.